BioCatalyst

GILD — GILEAD SCIENCES, INC. catalysts

2 verified catalyst event(s) for GILEAD SCIENCES, INC. (ticker GILD). Each is linked to its official source. Verified as of 2026-08-06.

Next verified catalyst

2026-09-01 — Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepati · official source ↗

Upcoming

DateEventCompanyDrugOfficial source & verification
2026-09 (month)
in 26d
ESTIMATED
 READOUT
Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chro
Phase 2 · Chronic Hepatitis B
 GILD GILEAD SCIENCES, INC. TAF ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
2026-09 (month)
in 26d
ESTIMATED
 READOUT
Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participa
Phase 2 · Non-small Cell Lung Cancer
 GILD GILEAD SCIENCES, INC. Sacituzumab Govitecan-hziy (SG), Pembrol ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.